Cost-effectiveness of pre-exposure HIV prophylaxis during pregnancy and breastfeeding in Sub-Saharan Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 72, Issue , 2016, Pages S145-S153

  Price, Joan T ^a   Wheeler, Stephanie B ^b   Stranix Chibanda, Lynda ^c   Hosek, Sybil G ^d   Heather Watts, D ^e   Siberry, George K ^f   Spiegel, Hans M L ^g   Stringer, Jeffrey S ^a   Chi, Benjamin H ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^d Jr Hospital of Cook County   (United States)

^e U S DEPARTMENT OF STATE   (United States)

^f EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Breastfeeding; Cost effectiveness; HIV prevention; Pre exposure prophylaxis; Pregnancy; Sub Saharan Africa

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AFRICA SOUTH OF THE SAHARA; ARTICLE; BREAST FEEDING; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; PRE-EXPOSURE PROPHYLAXIS; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; COST BENEFIT ANALYSIS; ECONOMICS; EPIDEMIOLOGY; HIV INFECTIONS; INFANT; NEWBORN; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; TRANSMISSION; VERTICAL TRANSMISSION;

AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; BREAST FEEDING; COST-BENEFIT ANALYSIS; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PRE-EXPOSURE PROPHYLAXIS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 84978903921     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000001063     Document Type: Article

References (91)

1. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367: 399-410.
2. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423-434.
3. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083-2090.
4. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363:2587-2599.
5. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509-518.
6. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-422.
7. Rees H, Delany-Moretlwe SA, Lombard C, et al. FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women. Seattle, WA: CROI; 2015.
8. Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373:2237-2246.
9. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53-60.
10. Bekker LG, Grant R, Hughes J, et al. HPTN 067/ADAPT Cape Town: a comparison of daily and nondaily PrEP dosing in African women. Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 23-26 February 2015.
11. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2015. Available at: http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index. html. Accessed January 25, 2016.
12. Centers for Disease Control and Prevention. Pre-exposure Prophylaxis for the Prevention of HIV Infection in the United States. 2014. Available at: http://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf. Accessed January 26, 2016.
13. UNICEF. Consultation on Clinical, Ethical and Operational Considerations for the Implementation of Oral Pre-exposure Prophylaxis (PrEP) in Sexually Active Older Adolescents (15-19) at High Risk of HIV Infection: Meeting Report. 2015. Available at: http://www.emtct-iatt.org/wp-content/uploads/2015/09/PrEP-Use-in-Adolescents-Consultation-Report-Vancouver-Canada-July-2015.pdf. Accessed December 7, 2015.
14. Alistar SS, Grant PM, Bendavid E. Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC Med. 2014;12:46.
15. Walensky RP, Park JE, Wood R, et al. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis. 2012;54:1504-1513.
16. Hallett TB, Baeten JM, Heffron R, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. Plos Med. 2011;8:e1001123.
17. Joint United Nations Programme on HIV/AIDS. The Gap Report. 2014. Available at: http://www.unaids.org/sites/default/files/media-asset/UNAIDS- Gap-report-en.pdf. Accessed January 26, 2016.
18. Drake AL, Wagner A, Richardson B, et al. Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis. Plos Med. 2014;11: e1001608.
19. Mugo NR, Heffron R, Donnell D, et al. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS. 2011;25:1887-1895.
20. Mugo NR, Hong T, Celum C, et al. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. JAMA. 2014;312:362-371.
21. Ehrhardt S, Xie C, Guo N, et al. Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence. Clin Infect Dis. 2015;60:275-278.
22. Fowler MG, Qin M, Fiscus SA, et al. Efficacy and safety of 2 strategies to prevent perinatal HIV transmission. Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 23-24 February, 2015.
23. Short CE, Douglas M, Smith JH, et al. Preterm delivery risk in women initiating antiretroviral therapy to prevent HIV mother-to-child transmission. HIV Med. 2014;15:233-238.
24. Darak S, Darak T, Kulkarni S, et al. Effect of highly active antiretroviral treatment (HAART) during pregnancy on pregnancy outcomes: experiences from a PMTCT program in western India. AIDS Patient Care STDS. 2013;27:163-170.
25. Watts DH, Williams PL, Kacanek D, et al. Combination antiretroviral use and preterm birth. J Infect Dis. 2013;207:612-621.
26. Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis. 2012;206:1695-1705.
27. Townsend C, Schulte J, Thorne C, et al. Antiretroviral therapy and preterm delivery-a pooled analysis of data from the United States and Europe. BJOG. 2010;117:1399-1410.
28. Tan-Torres Edejer T, Baltussen R, Adam T, et al. Making Choices in Health: WHO Guide to Cost-effectiveness Analysis. Geneva, Switzerland: World Health Organization; 2003.
29. The World Factbook. 2013. Available at: https://www.cia.gov/library/publications/the-world-factbook/rankorder/2004rank.html. Accessed January 26, 2016.
30. Moodley D, Esterhuizen T, Reddy L, et al. Incident HIV infection in pregnant and lactating women and its effect on mother-to-child transmission in South Africa. J Infect Dis. 2011;203:1231-1234.
31. Demographic and Health Surveys DHS. STATcompiler Database. Available at: http://beta.statcompiler.com. Accessed November 23, 2015.
32. World Health Organization. Global Health Observatory Data Repository. Available at: www.who.int/gho/en/. Accessed December 23, 2015.
33. Eligibility for ART in lower income countries collaboration, Wandel S, Egger M, et al. Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex Transm Infect. 2008;84(suppl 1):i31-i36.
34. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012;380: 2129-2143.
35. Marseille E, Giganti MJ, Mwango A, et al. Taking ART to scale: determinants of the cost and cost-effectiveness of antiretroviral therapy in 45 clinical sites in Zambia. PLoS One. 2012;7:e51993.
36. Bertozzi S, Gutierrez JP, Opuni M, et al. Estimating resource needs for HIV/AIDS health care services in low-income and middle-income countries. Health Policy. 2004;69:189-200.
37. Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med. 2011;155:209-216.
38. Marston M, Becquet R, Zaba B, et al. Net survival of perinatally and postnatally HIV-infected children: a pooled analysis of individual data from sub-Saharan Africa. Int J Epidemiol. 2011;40:385-396.
39. Marchant T, Willey B, Katz J, et al. Neonatal mortality risk associated with preterm birth in East Africa, adjusted by weight for gestational age: individual participant level meta-analysis. PLoS Med. 2012;9:e1001292.
40. Marinda E, Humphrey JH, Iliff PJ, et al. Child mortality according to maternal and infant HIV status in Zimbabwe. Pediatr Infect Dis J. 2007; 26:519-526.
41. Shapiro RL, Lockman S, Kim S, et al. Infant morbidity, mortality, and breast milk immunologic profiles among breast-feeding HIV-infected and HIV-uninfected women in Botswana. J Infect Dis. 2007;196:562-569.
42. Newell ML, Coovadia H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet. 2004;364:1236-1243.
43. The Breastfeeding and H. I. V. International Transmission Study Group, Coutsoudis A, Dabis F, et al. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis. 2004;189:2154-2166.
44. Murray CJ, Lopez A. The Global Burden of Disease. A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Boston, MA: The Harvard School of Public Health; 1996.
45. Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012;379:2162-2172.
46. Wedi CO, Kirtley S, Hopewell S, et al. Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis. Lancet HIV. 2015;3:e33-e48.
47. Chi BH, Vwalika B, Killam WP, et al. Implementation of the Zambia electronic perinatal record system for comprehensive prenatal and delivery care. Int J Gynaecol Obstet. 2011;113:131-136.
48. Tongo OO, Orimadegun AE, Ajayi SO, et al. The economic burden of preterm/very low birth weight care in Nigeria. J Trop Pediatr. 2009;55: 262-264.
49. Sicuri E, Bardaji A, Sigauque B, et al. Costs associated with low birth weight in a rural area of Southern Mozambique. PLoS One. 2011;6:e28744.
50. Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV pre-exposure prophylaxis (PrEP) for all populations: A systematic review and meta-analysis. AIDS. 2016. [epub ahead of print].
51. Lauer JA, Betran AP, Victora CG, et al. Breastfeeding patterns and exposure to suboptimal breastfeeding among children in developing countries: review and analysis of nationally representative surveys. BMC Med. 2004;2:26.
52. Tomasoni LR, Galli M, Declich S, et al. Knowledge, attitudes and practice (KAP) regarding newborn feeding modalities in HIV-infected and HIV-uninfected pregnant women in sub-Saharan Africa: a multicentre study. Int Health. 2011;3:56-65.
53. Bradley SEK, Mishra V. HIV and Nutrition Among Women in Sub-Saharan Africa. DHS Analytical Studies No. 16. Calverton, MD: Macro International Inc; 2008.
54. Clinton Health Access Initiative (CHAI). Antiretroviral Ceiling Price List. 2014. Available at: http://45.55.138.94/content/uploads/2015/05/CHAI-ARV-Ceiling-Price-2014-Final-English.pdf. Accessed December 23, 2015.
55. Cremin I, Alsallaq R, Dybul M, et al. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS. 2013;27:447-458.
56. Sweat M, Gregorich S, Sangiwa G, et al. Cost-effectiveness of voluntary HIV-1 counselling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzania. Lancet. 2000;356:113-121.
57. Bureau of Labor Statistics. Consumer Price Index. Available at: http://www.bls.gov/cpi/. Accessed January 25, 2016.
58. Ying R, Sharma M, Heffron R, et al. Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda. J Int AIDS Soc. 2015;18(4 suppl 3):20013.
59. Menzies NA, Berruti AA, Berzon R, et al. The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS. 2011;25:1753-1760.
60. Pretorius C, Stover J, Bollinger L, et al. Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS One. 2010;5:e13646.
61. World Health Organization. WHO Methods and Data Sources for Global Burden of Disease Estimates 2000-2011. Department of Health Statistics and Information Systems. Geneva, Switzerland. 2013. Available at: http://www.who.int/healthinfo/statistics/GlobalDALYmethods-2000-2011. pdf. Accessed December 23, 2015.
62. Collins IJ, Jourdain G, Hansudewechakul R, et al. Long-term survival of HIV-infected children receiving antiretroviral therapy in Thailand: a 5-year observational cohort study. Clin Infect Dis. 2010;51:1449-1457.
63. Johnson LF, Davies MA, Moultrie H, et al. The effect of early initiation of antiretroviral treatment in infants on pediatric AIDS mortality in South Africa: a model-based analysis. Pediatr Infect Dis J. 2012;31:474-480.
64. Gold MR, Siegel JE, Russel LB, et al. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
65. Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics. PLoS One. 2014;9:e86584.
66. Juusola JL, Brandeau ML, Owens DK, et al. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med. 2012;156:541-550.
67. Nichols BE, Boucher CA, van Dijk JH, et al. Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling study. PLoS One. 2013;8:e59549.
68. Gandhi M, Glidden DV, Liu A, et al. Strong correlation between concentrations of tenofovir (TFV) emtricitabine (FTC) in hair and TFV diphosphate and FTC triphosphate in dried Blood spots in the iPrEx open label extension: implications for pre-exposure prophylaxis adherence monitoring. J Infect Dis. 2015;212:1402-1406.
69. Matthews LT, Heffron R, Mugo NR, et al. High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2014;67:91-97.
70. Matthews LT, Sibeko S, Mansoor LE, et al. Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial. PLoS One. 2013;8:e56400.
71. Greenup AJ, Tan PK, Nguyen V, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol. 2014;61:502-507.
72. Townsend CL, Cortina-Borja M, Peckham CS, et al. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS. 2007;21:1019-1026.
73. Mugwanya KK, Wyatt C, Celum C, et al. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. JAMA Intern Med. 2015;175:246-254.
74. Solomon MM, Lama JR, Glidden DV, et al. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS. 2014;28:851-859.
75. Ransom CE, Huo Y, Patel K, et al. Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. J Acquir Immune Defic Syndr. 2013;64:374-381.
76. Siberry GK, Jacobson DL, Kalkwarf HJ, et al. Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy. Clin Infect Dis. 2015;61:996-1003.
77. Siberry GK, Williams PL, Mendez H, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS. 2012;26:1151-1159.
78. Gibb DM, Kizito H, Russell EC, et al. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med. 2012;9:e1001217.
79. Benaboud S, Pruvost A, Coffie PA, et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Côte d'Ivoire, in the ANRS 12109 TEmAA study, Step 2. Antimicrob Agents Chemother. 2011;55:1315-1317.
80. Siberry GK, Tierney C, Stranix-Chibanda L, et al. Impact of maternal tenofovir use on HIV-exposed newborn bone mineral. Conference on Retroviruses and Opportunistic Infections, Boston, MA, 22-25 February, 2016.
81. Grant RM, Liegler T. Weighing the risk of drug resistance with the benefits of HIV preexposure prophylaxis. J Infect Dis. 2015;211:1202-1204.
82. Rhee SY, Blanco JL, Jordan MR, et al. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient-and sequence-level meta-analysis. PLoS Med. 2015;12:e1001810.
83. Supervie V, Garcia-Lerma JG, Heneine W, et al. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci USA. 2010;107:12381-12386.
84. James KC, Foster SD. Weighing up disability. Lancet. 1999;354:87-88.
85. Jelsma J, Chivaura VG, Mhundwa K, et al. The global burden of disease disability weights. Lancet. 2000;355:2079-2080.
86. Ustun TB, Rehm J, Chatterji S, et al. Multiple-informant ranking of the disabling effects of different health conditions in 14 countries. WHO/NIH Joint Project CAR Study Group. Lancet. 1999;354:111-115.
87. Johri M, Norheim OF. Can cost-effectiveness analysis integrate concerns for equity? Systematic review. Int J Technol Assess Health Care. 2012; 28:125-132.
88. Rutstein SE, Price JT, Rosenberg NE, et al. Hidden costs: The ethics of cost-effectiveness analyses for health interventions in resource-limited settings. Glob Public Health. 2016. [epub ahead of print].
89. Gomez GB, Borquez A, Case KK, et al. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med. 2013;10: e1001401.
90. Brown G, Reeders D, Dowsett GW, et al. Investigating combination HIV prevention: isolated interventions or complex system. J Int AIDS Soc. 2015;18:20499.
91. Baltussen RM, Hutubessy RC, Evans DB, et al. Uncertainty in cost-effectiveness analysis. Probabilistic uncertainty analysis and stochastic league tables. Int J Technol Assess Health Care. 2002;18:112-119.